Nuclear Medicine Division
The Nuclear Medicine Division at UT Southwestern Medical Center performs clinical imaging, therapy, and research as well as preclinical research using novel radiopharmaceuticals.
The clinical work is performed at Parkland Memorial Hospital, Zale Lipshy University Hospital, William P. Clements Jr. University Hospital, and the PET Imaging Services at Clements Advanced Imaging Center. The division provides comprehensive clinical services, including general nuclear medicine, nuclear cardiology, oncologic PET/CT with 18F FDG (for human solid tumors), 18F DOTATATE (neuroendocrine tumors), 18F fluciclovine (prostate cancer), 18F sodium fluoride (bone metastases), cardiac PET/CT and brain PET/CT with 18F FDG and 18F-amyloid radiotracers. In addition, radionucleide therapies for benign thyroid disorders, malignant thyroid cancers, and bone metastases (Xofigo) are performed.
Research in Nuclear Medicine
Clinical research activities include National Cancer Institute-sponsored muticenter clinical trials in many human solid tumors, PET and SPECT neuroimaging for various neurodegenerative disorders, including novel tau radiotracers, and whole body imaging for oncologic disorders initiated by UT Southwestern investigators and cardiac PET/CT for cardiac diseases.
Preclinical imaging occurs in the Bill and Rita Clements Advanced Medical Imaging Building in laboratories containing state-of-the-art small animal PET/CT and SPECT/CT scanners and radiochemistry equipment.
Current areas of preclinical research include development of and in vivo testing of novel radiotracers to measure beta cell mass and function, tissue fibrosis, tumor localization, and physiology. Other areas of investigation include application of radionuclide to enhance nanoparticle technology development and application, use of copper radionuclides in imaging of neurodegenerative diseases, traumatic brain injury, and for imaging and therapy in prostate cancer, and use of mouse models of estrogen deficiency or resistance combined with imaging to understand how sex steroids regulate bone mass and metabolism.
Preclinical studies are supported by synthetic chemistry and radiochemistry, and frequently incorporate cell and molecular biology for a more comprehensive study of disease mechanisms and pathophysiology.